



Emergent BioSolutions to Release Full Year 2007 Financial Results and Conduct a Conference Call on March 7, 2008

February 25, 2008

ROCKVILLE, Md.--(BUSINESS WIRE)--Feb. 25, 2008--Emergent BioSolutions Inc. (NYSE: EBS) announced today that it will report financial results for the full year 2007 on Friday, March 7, 2008, before market open.

Company management will host a conference call at 9:00 am Eastern on March 7, 2008 to discuss these financial results, recent business developments and the outlook for 2008.

The conference call will be webcast and can be accessed from the Investor Relations section of the Company's website at www.emergentbiosolutions.com, under "Investors". Participants can also access the call by dialing 888.679.8040 or 617.213.4851 (international) and providing passcode EMERGENT (for those pre-registering, please use 36374368 as this is an automated service).

Emergent BioSolutions is offering call participants a pre-registration option that expedites access to the call and minimizes hold times. Pre-registrants will be issued a pin number to be used when dialing into the live call which will provide quick access to the conference call by bypassing the operator upon connection. Pre-registration is not mandatory. Those who would like to take advantage of pre-registration can do so by accessing the following website:

www.theconferencingservice.com/prereg/key.process?key=P3QNB6NDY

The conference call, replay and webcast will be open to all interested parties.

A replay of the teleconference will be available approximately one hour following the conclusion of the call by dialing 888/286-8010 or 617/801-6888 and using the passcode 97315959. The replay will be available through March 21. In addition, the webcast will be archived on the company's website, www.emergentbiosolutions.com, under "Investors".

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a profitable, multinational biopharmaceutical company dedicated to one simple mission -- to protect life. We develop, manufacture and commercialize immunobiotics, consisting of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Our products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Our marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. More information on the company is available at www.emergentbiosolutions.com.

CONTACT: Investors:

Robert G. Burrows, 301-795-1877

Vice President, Investor Relations

BurrowsR@ebsi.com

or

Media:

Tracey Schmitt, 301-795-1800

Director, Corporate Communications

SchmittT@ebsi.com

SOURCE: Emergent BioSolutions Inc.